AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19368793
Drug: 2microg Trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2microg Trivalent influenza DNA vaccine plus DEI‐LT
Trial: 16940406
Drug: Orlistat 60
RxNorm normalized name: orlistat 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 60 mg, given 3 times daily
Trial: 8100044
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg modafinil b.i.d.
Trial: 23774725
Drug: Neurofeedback combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofeedback combined with conventional treatment
Trial: 20221770
Drug: Pregabalin (PGB)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PGB) as mono- or add-on therapy, flexible-dosage, administered twice daily
Trial: 20221770
Drug: Non-Pregabalin therapy
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Non-Pregabalin therapy (change established doses and combinations of pre-existing mono- or combination therapy)
Trial: 18677810
Drug: Fengweicao Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fengweicao Granule (FWCG), 5 g orally twice a day for 3 months
Trial: 18677810
Drug: Proscar, 5
RxNorm normalized name: Proscar, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proscar, 5 mg per day for 3 months
Trial: 16911387
Drug: Calcipotriol/betamethasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol/betamethasone dipropionate ointment (Daivobet/Dovobet)
Trial: 12930031
Drug: Patient counseling
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient counseling on drug, diseases, and lifestyle modification from a pharmacist after a hospital visit.
Trial: 23542898
Drug: Human apoC‐III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human apoC‐III antisense drug
Trial: 16641119
Drug: Snus (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snus (oral moist snuff) consumption (n = 21) in ex-smokers
Trial: 11718043
Drug: Inappropriate initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inappropriate initial empirical antibiotic treatment
Trial: 9254255
Drug: Liposomes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomes with antibiotics and ectericide
Trial: 8129908
Drug: One type
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One type of vaccine
Trial: 28720395
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ACZ and NAC
Trial: 23237605
Drug: 0.01 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg.kg(‐1) penehyclidine hydrochloride
Trial: 16369129
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 1 x 300 or 480 microg s.c. prior to standard antibiotic treatment
Trial: 23445173
Drug: 2BOD (ball
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2BOD (ball attachment on two implants)
Trial: 23445173
Drug: 2ROD (bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ROD (bar attachment on two implants)
Trial: 23445173
Drug: 4ROD (bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4ROD (bar attachments on four implants)
Trial: 23328326
Drug: Hypnosis (hypnotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis (hypnotic analgesia suggestions)
Trial: 20492050
Drug: Preferred music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred music listening intervention (30-minute sessions, twice a week for six weeks)
Trial: 8150115
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRH‐a) discontinued as gonadotropin stimulation began
Trial: 8150115
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRH‐a) continued as gonadotropin stimulation began
Trial: 29876530
Drug: (Pyr(1))apelin‐13 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Pyr(1))apelin‐13 infusion
Trial: 29876530
Drug: (Pyr(1))apelin‐13 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Pyr(1))apelin‐13 infusion with concomitant phosphodiesterase type 5 inhibition
Trial: 22982658
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg orally twice daily for 2 months)
Trial: 20012601
Drug: Control (verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (verapamil 60 mg without lovastatin)
Trial: 17413685
Drug: Control PI
RxNorm normalized name: Pepto Diarrhea Control Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control PI drug(s) (CPI)
Trial: 16319551
Drug: Red grape
RxNorm normalized name: CVS Children's Cold & Cough Elixir (Red Grape)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red grape polyphenol extract (600 mg)
Trial: 16319551
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml of water)
Trial: 8568486
Drug: Formalin‐inactivated, alum‐adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (25 units, MSD) at 0, 24 weeks (group I)
Trial: 8568486
Drug: Formalin‐inactivated, alum‐adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (25 units, MSD) at 0, 2, 24 weeks (group II)
Trial: 2007359
Drug: Misoprostol 300
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 300 micrograms four times daily
Trial: 6284190
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) at 0.15 g/m2
Trial: 6284190
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) at 0.30 g/m2
Trial: 6284190
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) at 0.45 g/m2
Trial: 8906943
Drug: Nimodipine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (1.5 to 2.0 mg/kg/day) administered orally or as continuous intravenous drip for the first three days followed by oral therapy along with standard treatment.
Trial: 2319049
Drug: Self-guided behavioral
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-guided behavioral treatment (self-selected modules, randomly administered modules, no modules)
Trial: 508553
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of metoclopramide (5 and 10 mg)
Trial: 508553
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of metoclopramide (aqueous solution)
Trial: 508553
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of metoclopramide (slow release tablet)
Trial: 31679512
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care physiotherapy treatment
Trial: 18945396
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment (SSRIs)
Trial: 18945396
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment (other antidepressants)
Trial: 14650863
Drug: Fondaparinux for
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux for treatment of VTE (MATISSE DVT and MATISSE PE)
Trial: 14650863
Drug: Fondaparinux for
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux for treatment of acute coronary syndromes (PENTALYSE and PENTUA)
Trial: 10818057
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (chlorthalidone-based treatment)
Trial: 10818057
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with hypokalemia
Trial: 10818057
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with normal potassium levels
Trial: 8788488
Drug: Pindolol pre-treatment
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol pre-treatment
Trial: 1521944
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg/24 h)
Trial: 6442971
Drug: BCG and
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG and 5‐fluorouracil in combination with hydroxyurea, methyl‐CCNU and mitomycin C (regimen B)
Trial: 29484469
Drug: 8-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-day antibiotic therapy
Trial: 29484469
Drug: 15-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-day antibiotic therapy
Trial: 22922781
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for symptomatic convergence insufficiency
Trial: 11432682
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g) as a single intravenous dose at anesthetic induction
Trial: 11432682
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 g) plus clindamycin (0.6 g) administered intravenously at anesthetic induction and for two more doses at 8‐hourly intervals for a total of 3 days
Trial: 8407423
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent cisplatin and radiotherapy
Trial: 2439827
Drug: bopindolol (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bopindolol (1-2 mg daily)
Trial: 2439827
Drug: atenolol (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50-100 mg daily)
Trial: 30608598
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy using gemcitabine and S-1
Trial: 28964662
Drug: Levothyroxine (LT-4)
RxNorm normalized name: LT KIT
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (LT-4) replacement therapy for 2 months
Trial: 23195006
Drug: CNI-free maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI-free maintenance therapy
Trial: 23195006
Drug: Low-dose CNI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CNI therapy
Trial: 9530599
Drug: Irrigating solution
RxNorm normalized name: IRRIGATING SOLUTIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigating solution with heparin-sodium (10 IU/mL)
Trial: 9530599
Drug: Regular irrigating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular irrigating solution (control)
Trial: 30913208
Drug: Aspirin (100mg/d)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (100mg/d)
Trial: 30913208
Drug: Placebo (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for both fish oil and aspirin)
Trial: 26341548
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 400 μg salbutamol in standard posture
Trial: 26341548
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 200 μg salbutamol in standard posture
Trial: 26341548
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of salbutamol in forward leaning posture
Trial: 20713345
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 70/30 (BIAsp 30) + metformin
Trial: 20713345
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine + metformin + secretagogues
Trial: 14733417
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid (AA) 200 mg 3 times/week
Trial: 14733417
Drug: Low-dose desferroxamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose desferroxamine (DFO) 1 mg/Kg/week
Trial: 9168506
Drug: Intensive three-step
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive three-step protocol consisting of colistin inhalations and oral ciprofloxacin.
Trial: 9168506
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment (intensive protocol).
Trial: 9168506
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment with colistin inhalation and oral ciprofloxacin for 3 months.
Trial: 3541428
Drug: Purified chick
RxNorm normalized name: rabies vaccine, purified chick embryo cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified chick embryo cell vaccine
Trial: 3541428
Drug: Purified Vero
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Vero rabies vaccine
Trial: 3541428
Drug: Fetal bovine
RxNorm normalized name: Fetal Bovine Serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal bovine kidney cell vaccine
Trial: 3541428
Drug: HDCV (commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDCV (commercial human diploid cell vaccine)
Trial: 3541428
Drug: 2-1-1 postexposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-1-1 postexposure regimen (all vaccines)
Trial: 28439774
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous (IV) albumin infusion (n=100)
Trial: 28439774
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous (IV) albumin infusion within 2 hours of onset
Trial: 21716593
Drug: D-003 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-003 (10 mg/day)
Trial: 12562581
Drug: Tandospirone (5-HT(1A)
RxNorm normalized name: 5-HT
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone (5-HT(1A) agonist)
Trial: 10357321
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (5.4 mmol)
Trial: 1756347
Drug: Anti-anxiety drug
RxNorm normalized name: INVESTIGATIONAL ANTI-ANXIETY DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-anxiety drug
Trial: 26475420
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (DEX) 5 mg/d
Trial: 26475420
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (intravenous normal saline)
Trial: 26475420
Drug: Both DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both DEX and placebo treatments
Trial: 16761235
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin (0.3%) four times a day for 3 days
Trial: 16761235
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin (0.3%)
Trial: 15101564
Drug: Ziprasidone i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone i.m. 5 mg qid
Trial: 15101564
Drug: Ziprasidone i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone i.m. 10 mg qid
Trial: 15101564
Drug: Ziprasidone i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone i.m. 20 mg qid
Trial: 15101564
Drug: Haloperidol i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol i.m. up to 10 mg bid-qid
Trial: 15101564
Drug: Transition to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition to oral ziprasidone
Trial: 9845401
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d. and clarithromycin 500 mg b.d. for 2 weeks (RC)
Trial: 9845401
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d., clarithromycin 500 mg b.d. and metronidazole 400 mg b.d. for 1 week (RCM)
Trial: 2808259
Drug: More extensive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More extensive treatment experimental group
Trial: 2808259
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment control group
Trial: 1108582
Drug: etidocaine 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etidocaine 1.0% with adrenaline 5 mug/ml
Trial: 26880476
Drug: Internet-based Climate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Climate Schools: Ecstasy and Emerging Drugs module delivered once weekly for 4 weeks during health education classes.
Trial: 26880476
Drug: Internet-based Climate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Climate Schools: Ecstasy and Emerging Drugs module.
Trial: 11783328
Drug: XMT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XMT plus western medicine
Trial: 3514366
Drug: Intravaginal application
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal application of tablets containing PGE2
Trial: 17540227
Drug: Behavioral inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral inpatient treatment
Trial: 17540227
Drug: Psychodynamic inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic inpatient treatment
Trial: 17540227
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (both types)
Trial: 15040538
Drug: 4 mg/day
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/day of recombinant human growth hormone (rhGH) for 12 weeks
Trial: 15040538
Drug: Placebo, alternate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, alternate day or twice weekly dosing of rhGH
Trial: 3630804
Drug: Maintenance condition
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance condition (includes behavioral contracting and extended treatment)
Trial: 31285069
Drug: Daily exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exercise program for 30 days, once a day for 7-10 minutes.
Trial: 23419385
Drug: Midodrine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine plus standard medical therapy (SMT)
Trial: 23419385
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of midodrine and clonidine plus SMT
Trial: 21627522
Drug: Methadone IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone IV (0.3 mg/kg)
Trial: 21627522
Drug: Methadone OTM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone OTM (0.6 mg/kg)
Trial: 15041578
Drug: 0.8 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mL/kg of plain local anesthetic mixture (lidocaine 1% + bupivacaine 0.25% (50/50) + 1 microg/mL of fentanyl)
Trial: 15041578
Drug: 1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL/kg of the same mixture with 5 microg/mL of adrenaline
Trial: 11348933
Drug: Short-acting beta(2)-agonist
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta(2)-agonist (SA), n = 48
Trial: 11348933
Drug: Long-acting beta(2)-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta(2)-agonist (LA), n = 50
Trial: 9554298
Drug: Topical cyproterone
RxNorm normalized name: cyproterone
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyproterone acetate lotion (20 mg)